tetrapeptide repeat homeobox like (pseudogene)Genealiases: []
Q-omics provides the consensus-scored TPRXL profile across patient tissues and cancer cell-line models. TPRXL expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TPRXL is differentially expressed in 14, with the highest sampling consensus in LUSC. Additionally, TPRXL RNA expression shows 12,302 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, LUSC, and ESCA as cancer lineages where TPRXL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPRXL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPRXL survival associations across molecular data types. TPRXL RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPRXL RNA expression–survival associations across cancer types. High TPRXL expression shows unfavorable associations in ACC, LIHC and BRCA, but favorable associations in UVM, UCS and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TPRXL RNA expression.
This table summarizes TPRXL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TPRXL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPRXL shows lower tumor expression in KIRC and KICH and higher tumor expression in LUSC, COAD, BRCA and LIHC. The LUSC box plot shows higher TPRXL RNA expression in tumor versus normal tissue (log2 FC = +3.135, t-test p < 0.001).
This table shows molecular features associated with TPRXL in patient tissues and cancer cell lines. In patient samples, TPRXL shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TPRXL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
